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Background: Current research criteria for Alzheimer’s disease (AD) include cerebrospinal
fluid (CSF) biomarkers into the diagnostic algorithm. However, spreading their use to the
clinical routine is still questionable.
Objective: To provide an updated, systematic and critical review on the diagnostic utility
of the CSF core biomarkers for AD.
Data sources: MEDLINE, PreMedline, EMBASE, PsycInfo, CINAHL, Cochrane Library, and
CRD.
Eligibility criteria: (1a) Systematic reviews with meta-analysis; (1b) Primary studies pub-
lished after the new revised diagnostic criteria; (2) Evaluation of the diagnostic performance
of at least one CSF core biomarker.
Results:The diagnostic performance of CSF biomarkers is generally satisfactory. They are
optimal for discriminating AD patients from healthy controls. Their combination may also
be suitable for mild cognitive impairment (MCI) prognosis. However, CSF biomarkers fail
to distinguish AD from other forms of dementia.
Limitations: (1) Use of clinical diagnosis as standard instead of pathological postmortem
confirmation; (2) variability of methodological aspects; (3) insufficiently long follow-up peri-
ods in MCI studies; and (4) lower diagnostic accuracy in primary care compared with
memory clinics.
Conclusion: Additional work needs to be done to validate the application of CSF core bio-
markers as they are proposed in the new revised diagnostic criteria. The use of CSF core
biomarkers in clinical routine is more likely if these limitations are overcome. Early diagno-
sis is going to be of utmost importance when effective pharmacological treatment will be
available and the CSF core biomarkers can also be implemented in clinical trials for drug
development.
Keywords: Alzheimer’s disease, cerebrospinal fluid biomarkers, amyloid beta-protein (42), tau protein, sensitivity,
specificity, meta-review, state-of-the-art review
1. INTRODUCTION
Dementia is becoming a worldwide problem causing a tremendous
burden to the public health system and society (http://www.alz.
org/documents_custom/trajectory.pdf ; Ferri et al., 2010). Among
different types of dementia, Alzheimer’s disease (AD) is the
most common form, affecting more than 27 million people and
accounting for 60–70% of all dementia cases (Hebert et al.,
2003; Brookmeyer et al., 2007). Therefore, effective strategies for
early diagnosis, prevention and treatment are urgently needed.
Regarding diagnosis, the clinical criteria established in 1984 by
the NINCDS–ADRDA (McKhann et al., 1984) has recently been
revised by the National Institute on Aging and the Alzheimer Asso-
ciation (Jack et al., 2011; McKhann et al., 2011). These criteria for
AD incorporate two notable differences. First, the AD process is
considered as a continuum that encompasses three different dis-
ease stages: (1) preclinical phase, in which subjects are cognitively
normal but have AD pathology; (2) symptomatic pre-dementia
phase: mild cognitive impairment (MCI); and (3) dementia phase:
AD (Jack et al., 2011). Second, this pathophysiological process can
be studied in vivo by means of different biomarkers.
A biomarker is a measurable biological feature that can be used
to diagnose or predict a physiological or pathological condition
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(Barber, 2010). Main AD biomarkers investigated so far may be
broken into two classes based on the biological aspect they mea-
sure. Biomarkers of brain amyloid-beta (Aβ) protein depositions
are low cerebrospinal fluid (CSF) Aβ42 and positive PET amyloid
imaging (Jack et al., 2008; Chételat et al., 2010). Biomarkers of
downstream neuronal degeneration or injury are elevated CSF tau
(both total tau and hyperphosphorylated tau: p-tau); decreased
18 fluorodeoxyglucose (FDG) uptake on PET in temporo–parietal
cortex; and disproportionate atrophy on structural magnetic res-
onance imaging (MRI) in medial, basal, and lateral temporal
lobe, and medial parietal cortex. These biomarkers have been
integrated into a hypothetical model published by Jack et al.
(2010a). According to this model, biomarkers of Aβ accumu-
lation become abnormal first, being Aβ accumulation necessary
but not sufficient to produce the clinical symptoms of MCI and
dementia. Biomarkers of neuronal injury and neurodegeneration
are abnormal later, retaining a close relationship with cognitive
performance through the clinical phases of MCI and dementia
(Vemuri et al., 2010). However, autopsy data suggest that tau
pathophysiology might precede Aβ deposition (Braak and Del
Tredici, 2011). This apparently conflicting evidence has been inte-
grated in a recent revision of the model (Jack et al., 2013). Aβ
and tau pathophysiological processes might be initiated indepen-
dently in sporadic AD. Subcortical tauopathy might occur first
although it is only detectable by immunostaining methods. Aβ
pathophysiology arises later and independently from pre-existing
tauopathy. Through unknown mechanisms, Aβ pathophysiol-
ogy would accelerate the antecedent subcortical tauopathy lead-
ing to neocortical spread of neurofibrillary tangles (Jack et al.,
2013).
This meta-review is focused on CSF biomarkers. Although sig-
nificant advances have been made in the field of neuroimaging,
biomarkers based on CSF are at present the most convenient for
studying disease progression (Hampel et al., 2008; Anoop et al.,
2010; Monge-Argilés et al., 2010). CSF biomarkers reflect key
neuropathological hallmarks of AD, i.e., amyloid plaques and neu-
rofibrillary tangles (Braak and Braak, 1991; Thal et al., 2002). Accu-
mulation of amyloid plaques and neurofibrillary tangles probably
starts 20–30 years before the clinical onset of the disease. There-
fore, CSF biomarkers are the most suitable candidates to facilitate
AD diagnosis in the very early stages of the disease, long before
symptoms onset. Moreover, since it may be optimal to treat the
neuropathology as early as possible, biomarkers of preclinical AD
are likely to play a pivotal role in the development of the next
generation of therapies.
Numerous studies on CSF biomarkers for AD have been pub-
lished during the last years, however frequently providing contra-
dictory and inconclusive results. In this sense, the fact of spreading
the use of CSF biomarkers to the clinical routine is still question-
able. An effort has not been done yet to systematically define the
state-of-the-art since the new revised research criteria for AD were
published in May 2011. It is therefore timely and highly necessary
to integrate all the information available in the literature, evaluate
the findings, and assess the diagnostic efficiency of CSF biomark-
ers. Only in this sense it will be possible to answer the relevant
question of for which patients these CSF biomarkers can be useful
in the clinical practice.
2. OBJECTIVES
Since the CSF core biomarkers have been incorporated to the
current diagnostic criteria for AD for complementing clinical
impression with biological support of AD pathology, the primary
objective of this meta-review is to present an updated systematic
and critical review on the diagnostic performance of the CSF core
biomarkers for AD (Aβ42, T-tau, and p-tau).
In particular, we aim to answer three specific questions. The
first two addresses the issue of AD diagnosis and the third one is
related to AD prediction:
(1) What is the diagnostic efficiency of CSF Aβ42, T-tau, and p-tau
for the diagnosis of AD vs. healthy controls?
(2) What is the diagnostic efficiency of CSF Aβ42, T-tau, and p-
tau for the diagnosis of AD vs. other dementias: dementia
with Lewy bodies (DLB), frontotemporal lobar degenera-
tion (FTLD), vascular dementia (VaD), and Creutzfeldt–Jakob
disease (CJD)?
(3) What is the diagnostic efficiency of CSF Aβ42, T-tau, and p-tau
for the early detection of MCI patients that will progress to
AD vs. MCI patients that will remain stable over time?
In order to address these questions, we reviewed system-
atic reviews with meta-analysis as well as primary studies pub-
lished after the publication of the new revised diagnostic criteria.
These studies include case–control studies with prospective or
retrospective, cross-sectional or longitudinal designs.
3. MATERIALS AND METHODS
3.1. SEARCH METHODS
A systematic review was conducted for the period between Jan-
uary 1990 and September 2013. Consulted electronic databases
were MEDLINE and PreMedline, EMBASE, PsycInfo, CINAHL,
Cochrane Library, and CRD. The search strategy was developed for
each database using the combination of the following medical sub-
ject heading (MeSH) and free-text terms: “AD diagnosis” or “AD”,
and “abeta-42” or “T-tau” or “P-tau” or “tau” or “phospho-tau”
or “phosphorylated tau”. Examples of the search strategy followed
for the two major databases are shown in Table A1 in Appen-
dix (MEDLINE–OVID) and Table A2 in Appendix (EMBASE–
Elsevier). In addition, reference sections of included reports were
searched to identify relevant publications. Researchers thought
likely to have carried out relevant studies were also contacted.
Studies addressing CSF Aβ42, T-tau, and p-tau in AD but primarily
focusing in other conditions were also covered.
3.2. STUDY SELECTION
Initial inclusion criteria for the current review were studies that:
(1) included a systematic review with meta-analysis; (2) evalu-
ated the diagnostic performance of at least one of the CSF core
biomarkers for AD (Aβ42, T-tau, and/or P-tau); and (3) were pub-
lished in English or Spanish. Exclusion criteria were studies that:
(1) did not follow a rigorous process of systematic review (defin-
ing the question, finding the evidence, documenting the search
process, and appraising and selecting suitable studies), and (2) did
not provide any meta-analysis.
Two reviewers performed the study selection (Daniel Ferreira,
Lilisbeth Perestelo-Perez). Peer review was done independently. In
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case of doubt and/or disagreements a third reviewer was consulted
(Pedro Serrano-Aguilar). A total of 1,770 records were identified in
the initial search. Duplicated articles were removed and remaining
1,304 publications were screened from title and abstract accord-
ing to selection criteria. Sixty-three potentially relevant studies
were then gathered and full text examined. Finally, seven articles
completely fulfilled the selection criteria: Bloudek et al. (2011),
Diniz et al. (2008), Mitchell (2009), Monge-Argilés et al. (2010),
Schmand et al. (2010); Sunderland et al. (2003), and Van Harten
et al. (2011). They all were systematic reviews with meta-analyses.
Selection flow including reasons for study exclusion at each phase
is fully detailed in Figure 1.
As noted above, the original scope of this meta-review was to
identify systematic reviews with meta-analyses. However, we did
not detect any of these studies published after the new revised
criteria for AD (May 2011). Hence, in order to synthesize the avail-
able evidence from May 2011 to the date of our search (September
2013), we decided to carry out a specific search for primary studies.
Inclusion criteria were studies that: (1) were accepted and/or pub-
lished after May 2011; (2) evaluated the diagnostic performance
of at least one of the CSF core biomarkers for AD (Aβ42, T-tau,
and/or P-tau); and (3) were published in English or Spanish. Same
combination of MeSH and free-text terms was applied although
including specifications for primary studies. From a total of 220
records, 26 studies fulfilled inclusion criteria and were selected
for this specific evidence-based synthesis. Complete selection flow
and reasons for study exclusion are fully detailed in Figure 2.
3.3. DATA COLLECTION, RISK OF BIAS AND EVALUATION OF
METHODOLOGICAL QUALITY
A data extraction sheet was developed to collect relevant data
by covering: author and publication year, country, objectives,
search methods, study selection, study design, CSF biomarkers
evaluated, characteristics of diagnostic groups, statistical analy-
ses, results (diagnostic accuracy and main findings), and con-
clusions. Data extraction was carried out by a single researcher
(Daniel Ferreira) for each eligible study. A second researcher
verified the extracted data with the original sources to ensure
the quality and accuracy of the extraction (Lilisbeth Perestelo-
Pérez).
Differential handling of positive results compared to nega-
tive results lead to a misleading bias in the overall published
literature. Therefore, published studies may not be truly rep-
resentative of all valid studies undertaken, and this bias may
affect systematic reviews and meta-analyses. Several strategies
were thus followed in order to reduce the risk of bias related
to publication, data availability, and reviewer selection (see
Table A3 in Appendix). Moreover, users’ guides published by
Oxman et al. (1994) and PRISMA statement (Liberati et al.,
2009; Moher et al., 2009) were used to critically evaluate the
methodological quality of included systematic reviews with meta-
analyses. Finally, this study was performed in accordance with
the PRISMA statement, which provides a detailed guideline
of preferred reporting style for systematic reviews and meta-
analyses.
3.4. OUTCOME MEASURES AND STATISTICAL ANALYSES
For each CSF core biomarker (Aβ42, T-tau, and p-tau), the fol-
lowing outcome measures of diagnostic ability were considered:
sensitivity, specificity, and diagnostic accuracy [positive predictive
value (PPV); negative predictive value (NPV)]. Means, standard
deviations, and maximum and minimum values for sensitivity and
specificity were calculated for primary studies. In addition, likeli-
hood ratios were calculated from mean sensitivity and specificity
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FIGURE 1 | Study selection flow for systematic reviews with meta-analyses.
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values provided in the systematic reviews with meta-analysis and
primary studies:
Positive likelihood ratio (LR+) = sensitivity/(1− specificity)
Negative likelihood ratio (LR−) = (1− sensitivity)/specificity
4. RESULTS
4.1. SYSTEMATIC REVIEWSWITH META-ANALYSIS
4.1.1. Main characteristics of studies and methodological quality
Among the seven systematic reviews with meta-analyses included
in this meta-review, three refer to the diagnostic ability of CSF
core biomarkers to discriminate AD vs. healthy controls (Sun-
derland et al., 2003; Mitchell, 2009; Bloudek et al., 2011). Three
studies include patients with AD vs. other dementias (Mitchell,
2009; Bloudek et al., 2011; Van Harten et al., 2011). More specif-
ically, Bloudek et al. (2011) and Mitchell (2009), compared AD
to a mixed group including different types of dementia. Only
Van Harten et al. (2011) specified separated groups of demen-
tia: DLB, FTLD, VaD, and CJD. Finally, four studies describe the
ability of CSF core biomarkers to differentiate patients with MCI
who progress to AD or other dementias [MCI-converters (MCI-
C)] compared with patients with MCI who remain stable over time
[MCI-stable (MCI-S)] (Diniz et al., 2008; Mitchell, 2009; Monge-
Argilés et al., 2010; Schmand et al., 2010). Table 1 summarizes
the main characteristics of each selected systematic review with
meta-analysis.
Scores in the Oxman’s scale are presented in Table A4 in Appen-
dix. All the included systematic reviews with meta-analysis had
total scores between 7 and 8, which correspond to satisfactory
methodological quality (Oxman et al., 1994). PRISMA check-
list is presented in Table A5 in Appendix, showing reporting
transparence of the different systematic reviews.
4.1.2. Diagnostic performance of CSF core biomarkers for AD
Results from included systematic reviews with meta-analysis are
presented below according to the specific objectives of this meta-
review. The first section includes the comparison between AD
and healthy controls. The second section details the differential
diagnosis between AD and other dementias. The third and last
section addresses the discrimination between MCI-C and MCI-S.
For each section, information is presented separately for the three
different biomarkers as well as possible combinations between
them. Tables 2–4 summarize mean sensitivity and specificity val-
ues provided in the various meta-analyses, as well as corresponding
likelihood ratios.
4.1.3. AD vs. healthy controls
4.1.3.1. Aβ42. Decreased CSF Aβ42 concentrations to about
50% have frequently been reported in AD patients when compared
to healthy controls. However, no reductions and even higher levels
have also been reported. Sunderland et al. (2003) included 17 stud-
ies in their meta-analyses. A clear reduction in Aβ42 was found in
14 studies, while 2 studies were equivocal (Fukuyama et al., 2000;
Csernansky et al., 2002), and another reported increased levels of
Aβ42 in the AD group (Jensen et al., 1999). About the diagnostic
utility of CSF Aβ42, Bloudek et al. (2011) reported a mean sen-
sitivity of 80% (95% CI= 73–85%) and specificity of 82% (95%
CI= 74–88%).
4.1.3.2. T-tau. An increase by approximately 300% in the total
concentration of tau in CSF has been found in many studies com-
paring AD patients vs. normal controls. In the meta-analysis per-
formed by Sunderland et al. (2003), significant differences in CSF
T-tau levels were obtained in all reviewed studies. About the diag-
nostic utility of T-tau, Bloudek et al. (2011) reported sensitivity of
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Table 2 | Systematic reviews with meta-analyses (AD vs. healthy controls): sensitivity and specificity values.
CSF biomarker and
study
Number of
studies included
Number of
AD patients
Number of
healthy controls
Sensitivity
(95% CI)
Specificity
(95% CI)
LR+ LR−
Aβ42
Bloudek et al. (2011) 14 ns ns 80 (73–85) 82 (74–88) 4 0.2
T-TAU
Bloudek et al. (2011) 22 ns ns 82 (76–87) 90 (86–93) 8 0.2
p-TAU
Mitchell (2009) 19 1329 971 78 (71–84) 88 (84–91) 7 0.3
Bloudek et al. (2011) 14 ns ns 80 (70–87) 83 (75–88) 5 0.2
COMBINATION OF Aβ42 ANDT-TAU
Bloudek et al. (2011) 11 ns ns 89 (84–92) 87 (83–90) 7 0.1
AD, Alzheimer’s disease; CI, confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio; ns, non-specified; sensitivity and specificity values are
expressed in percentages.
Table 3 | Systematic reviews with meta-analyses (AD vs. other dementias): sensitivity and specificity values.
CSF biomarker and
Study
Number of
studies included
Number of
AD patients
Number of non-AD
demented patients
Sensitivity
(95% CI)
Specificity
(95% CI)
LR+ LR−
Aβ42
Bloudek et al. (2011) 12 ns ns 73 (67–78) 67 (62–72) 2 0.4
T-TAU
Bloudek et al. (2011) 19 ns ns 78 (72–83) 75 (68–81) 3 0.3
Van Harten et al. (2011) 19 473 DLB: 208 73 (62–84) 90 (85–95) 7 0.3
22 1330 FTLD: 464 74 (66–82) 74 (66–81) 3 0.4
23 1048 VaD: 306 73 (60–86) 86 (80–90) 5 0.3
7 175 CJD: 110 91 (86–96) 98 (97–100) 46 0.09
p-TAU
Mitchell (2009) 18 1304 588 72 (63–80) 78 (72–83) 3 0.4
Bloudek et al. (2011) 20 ns ns 79 (72–84) 80 (71–86) 4 0.3
Van Harten et al. (2011) 9 531 DLB: 210 74 (68–80) 83 (76–89) 4 0.3
14 607 FTLD: 249 79 (67–90) 83 (76–90) 5 0.3
13 333 VaD: 165 88 (72–92) 78 (68–88) 4 0.15
COMBINATION OF Aβ42 ANDT-TAU
Bloudek et al. (2011) 7 ns ns 86 (79–91) 67 (53–79) 3 0.2
AD, Alzheimer’s disease; CI, confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio; ns, non-specified; sensitivity and specificity values are
expressed in percentages; DLB, dementia with Lewy bodies; FTLD, frontotemporal lobe degeneration; VaD, vascular dementia; CJD, Creutzfeldt–Jakob disease.
82% (95% CI= 76–87%) and specificity of 90% (95% CI= 86–
93%). As it can be seen in Table 2, T-tau has the highest LR+ (=8),
indicating moderate increase in the likelihood of the disease.
4.1.3.3. p-tau. p-tau concentration in CSF is also increased in
AD when compared to healthy controls. Mean sensitivity values
are around 80% [Mitchell (2009): 78%, with 95% CI= 71–84%;
Bloudek et al. (2011): 80%, with 95% CI= 70–87%], while speci-
ficity is lightly higher [Mitchell (2009): 88%, with 95% CI= 84–
91%; Bloudek et al. (2011): 83%, with 95% IC= 75–88%]. In
addition, according to the meta-analyses performed by Mitchell
(2009), PPV and NPV values were 90 and 73%, respectively. P-tau
would facilitate 81.8 correct diagnoses for every 100 individuals
tested. Different tau epitopes (p181, p199, and p231) had similar
values, showing no significant differences between them.
4.1.3.4. Combination of CSF core biomarkers. Only Bloudek
et al. (2011) included the combination of several CSF core bio-
markers on their meta-analyses. Results for the combination of
Aβ42 and tau through 11 different studies gave a mean sensitivity
of 89% (95% CI= 84–92%) and a mean specificity of 87% (95%
CI= 83–90%). Moreover, as it is detailed in Table 2, the combina-
tion of Aβ42 and T-tau has the lowest LR− (=0.1), with moderate
decrease in the likelihood of the disease.
4.1.4. AD vs. other dementias
4.1.4.1. Aβ42. The meta-analyses performed by Bloudek et al.
(2011) showed that CSF Aβ42 distinguished AD patients from non-
AD demented patients with a sensitivity of 73% (95% CI= 67–
78%) and a specificity of 67% (95% CI= 62–72%). However,
different forms of dementia were pooled together. We have not
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Table 4 | Systematic reviews with meta-analyses (MCI-C vs. MCI-S): sensitivity and specificity values.
CSF biomarker and study Number of
studies included
Number of
MCI-C patients
Number of
MCI-S patients
Sensitivity
(95% CI)
Specificity
(95% CI)
LR+ LR−
Aβ42
Monge-Argilés et al. (2010) 6 128 216 67 (59–75) 71 (65–78) 2 0.5
T-TAU
Monge-Argilés et al. (2010) 11 213 383 82 (76–86) 70 (65–75) 3 0.3
p-TAU
Mitchell (2009)a 6 163 225 81 (69–91) 65 (50–80) 2 0.3
Monge-Argilés et al. (2010) 7 157 306 81 (75–87) 76 (70–81) 3 0.3
COMBINATION OF Aβ42 ANDT-TAU
Monge-Argilés et al. (2010) 3 101 164 81 (72–88) 87 (81–91) 6 0.2
MCI, mild cognitive impairment (MCI-C: MCI-converters, MCI-S: MCI-stables); CI, confidence interval; LR+, positive likelihood ratio; LR−, negative likelihood ratio;
sensitivity and specificity values are expressed in percentages;
aMCI patients who progress to dementia (non-necessarily AD).
found further systematic reviews with meta-analyses comparing
AD against other specific forms of dementia.
4.1.4.2. T-tau. The meta-analyses performed by Bloudek et al.
(2011) showed that CSF T-tau distinguished AD patients from
non-AD demented patients with a sensitivity of 78% (95%
CI= 72–83%) and a specificity of 75% (95% CI= 68–81%). In
addition, Van Harten et al. (2011) published a detailed meta-
analysis reporting sensitivity and specificity values for the dif-
ferential diagnosis of AD against other specific entities as DLB,
FTLD, VaD, and CJD. Regarding DLB, in spite of the consider-
ably variability between studies, CSF T-tau levels are generally
much lower in DLB than in AD. The meta-analyses performed by
Van Harten et al. (2011) yielded a mean sensitivity of 73% (95%
CI= 62–84%) and specificity of 90% (95% CI= 85–95%). CSF
T-tau levels are also much lower in FTLD than AD. Since FTLD
usually occurs before the age of 65, comparison with early-onset
AD is relevant. When only patients with early-onset AD were ana-
lyzed, differences between FTLD and AD were even larger. In van
Harten’s meta-analyses, sensitivity and specificity were both 74%
(sensitivity: 95% CI= 66–82%; specificity: 95% CI= 66–81%). T-
tau CSF concentrations in VaD patients are far lower than in AD
patients. In the same study,Van Harten et al. (2011) reported a sen-
sitivity of 73% (95% CI= 60–86%) and specificity of 86% (95%
CI= 80–90%). Finally, numerous studies have shown that CJD
is characterized by extremely high CSF T-tau values as compared
with AD (at least 10-fold higher). Van Harten et al. (2011) obtained
a sensitivity of 91% (95% CI= 86–96%) and specificity of 98%
(95% CI= 97–100%). Table 3 shows likelihood ratios for the two
meta-analyses. Results indicate that when comparing AD vs. CJD,
T-tau offers an extremely high capacity to rule-in AD patients
(LR+= 46) and rule-out non-AD cases (LR−= 0.09). Moreover,
T-tau turned out to be moderately appropriated to rule-in AD
patients when compared to DLB (LR+= 7) and VaD (LR+= 5).
4.1.4.3. p-tau. The diagnostic utility of CSF p-tau for AD
against other dementias has been meta-analyzed by Bloudek
et al. (2011); Mitchell (2009), and Van Harten et al. (2011).
Both Mitchell and Bloudek presented sensitivity and specificity
values for AD compared with a pooled group of different
forms other non-AD dementias. Bloudek et al. (2011) obtained
slightly higher sensitivity and specificity values (sensitivity: 79%,
95% CI= 72–84%; specificity: 80%, 95% CI= 71–86%). Mitchell
(2009) reported a mean sensitivity of 72% (95% CI= 63–80%)
and specificity of 78% (95% CI= 72–83%), with a PPV of 86%
and NPV of 58%. Thus, p-tau would facilitate 73.7 correct diag-
noses for every 100 individuals with dementia tested. An analysis
about the specific p-tau epitopes showed that p181 appeared to be
significantly less sensitive than either p199 or p231. In addition,
p231 was significantly less specific than either p199 or p181. How-
ever, given the limited data for p199 and p231 these findings must
be considered provisional. On the other hand, Van Harten et al.
(2011) reported sensitivity and specificity values for the differential
diagnosis of AD against specific forms of non-AD dementias. In
relation to DLB, CSF p-tau levels were lower than in AD, with a sen-
sitivity of 74% (95% CI= 68–80%) and specificity of 83% (95%
CI= 76–89%). CSF p-tau levels in FTLD were also lower than
in AD. Sensitivity was 79% (95% CI= 67–90%), and specificity
83% (95% CI= 76–90%). Regarding VaD, CSF p-tau values were
also lower than in AD, with a sensitivity of 88% (95% CI= 72–
92%), and specificity of 78% (95% CI= 68–88%). Patients with
combined AD and VaD have elevated concentrations of T-tau and
P-tau compared with AD patients. Finally,Van Harten et al. (2011)
also presented some considerations for CJD related to AD. CSF
p-tau alone has not been sufficiently investigated as diagnostic
marker to differentiate both diagnostic categories. However, var-
ious studies indicate that CSF p-tau concentrations on CJD are
relatively less increased compared with concentrations of T-tau.
Moreover, two original studies combining T-tau and P-tau values
showed very good diagnostic performance when comparing CJD
and AD patients, with a sensitivity of 91–100% and specificity of
97–100% (Buerger et al., 2006; Matsui et al., 2010). Likelihood
ratios presented in Table 3 show that p-tau is suitable to rule-in
AD patients when compared to FTLD (LR+= 5), and to rule-out
non-AD cases when compared to VaD (LR−= 0.15).
4.1.4.4. Combination of CSF core biomarkers. Bloudek et al.
(2011) reported in their meta-analysis a mean sensitivity of 86%
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(95% CI= 79–91%) and specificity of 67% (95% CI= 53–79%)
when combining CSF levels of Aβ42 and tau. This combination did
not significantly increase the likelihood of AD vs. other dementias
(LR+= 3), but could be suitable to rule-out non-AD cases in the
same context (LR−= 0.2).
4.1.5. MCI-C vs. MCI-S
4.1.5.1. Aβ42. At baseline, MCI-C have lower levels of CSF Aβ42
as compared to MCI-S, to controls, and even to those who have
any additional decline yet not sufficient to reach the diagnos-
tic threshold for dementia or AD (MCI-P) (Diniz et al., 2008;
Schmand et al., 2010). Moreover, in the meta-analyses carried out
by Diniz et al. (2008), CSF Aβ42 levels were similar for MCI-
C and AD patients. Only one study demonstrated a significant
reduction of CSF Aβ42 between baseline and follow-up assess-
ments in MCI-C patients (Andreasen et al., 2003). Interestingly,
another study showed that MCI patients with lower CSF Aβ42
values had a faster progression to AD (Herukka et al., 2007).
In regards to the diagnostic utility of CSF Aβ42 to distinguish
MCI-C from MCI-S, Monge-Argilés et al. (2010) reported a sensi-
tivity of 67% (95% CI= 59–75%), and a specificity of 71% (95%
CI= 65–78%).
4.1.5.2. T-tau. MCI-C and MCI-P have higher CSF T-tau lev-
els at baseline as compared to MCI-S patients and controls. In
contrast, MCI-C and AD patients have similar CSF T-tau levels
(Diniz et al., 2008; Schmand et al., 2010). Monge-Argilés et al.
(2010), reported a sensitivity of 82% (95% CI= 76–86%), and a
specificity of 70% (95% CI= 65–75%).
4.1.5.3. p-tau. Cerebrospinal fluid p-tau levels in MCI-C
patients are also higher at baseline as compared to MCI-S and
controls (Diniz et al., 2008; Schmand et al., 2010). Regard-
ing the diagnostic utility of CSF p-tau to distinguish MCI-C
from MCI-S, Monge-Argilés et al. (2010) reported a sensitiv-
ity of 81% (95% CI= 75–87%) and specificity of 76% (95%
CI= 70–81%). Moreover, Mitchell (2009) studied CSF p-tau
ability to distinguish between MCI patients who progress to
dementia (not necessarily AD), and MCI-S. Sensitivity was also
81% (95% CI= 69–91%). However, mean specificity fell down
to 65% (95% CI= 50–80%). According to Mitchell’s analyses,
p-tau would be expected to facilitate 71.9 correct diagnoses
for every 100 individuals tested. The predicted PPV would be
63% and the NPV 83%, suggesting that p-tau might be best
used to predict who would not progress rather than who might
deteriorate.
4.1.5.4. Combination of CSF core biomarkers. According to
the meta-analysis performed by Diniz et al. (2008), in general,
the association of two or three different CSF biomarkers yielded
higher sensitivity and specificity values than each biomarker alone.
Monge-Argilés et al. (2010) indicated a mean sensitivity of 81%
(95% CI= 72–88%), and a specificity of 87% (95% CI= 81–91%).
Moreover, likelihood ratios show that this combination also has the
best capacity to rule-in MCI-C patients (LR+= 6) and to rule-out
non-MCI-C patients (LR−= 0.2).
4.2. PRIMARY STUDIES PUBLISHED AFTER THE NEW REVISED
DIAGNOSTIC CRITERIA
The specific search for studies published between May 2011 and
September 2013 resulted in 26 unique eligible references. Fourteen
refer to the diagnostic ability of CSF core biomarkers to discrimi-
nate between AD and healthy controls (Bjerke et al., 2011; Baldeiras
et al., 2012; Ewers et al., 2012; Mattsson et al., 2012; Mouton-Liger
et al., 2012; Parnetti et al., 2012; Westman et al., 2012; Yang et al.,
2012; Bombois et al., 2013; Guo et al., 2013; Lampert et al., 2013;
Le Bastard et al., 2013; Molinuevo et al., 2013; Toledo et al., 2013).
Eight studies include patients with AD vs. other dementias (Bjerke
et al., 2011; Bibl et al., 2012; de Rino et al., 2012; Irwin et al., 2012;
Toledo et al., 2012; Gabelle et al., 2013; Le Bastard et al., 2013;
Muñoz-Ruiz et al., 2013). Twelve studies describe the ability of
CSF core biomarkers to differentiate between MCI-C and MCI-S
(Buchhave et al., 2012; Ewers et al., 2012; Mattsson et al., 2012;
Parnetti et al., 2012; Vos et al., 2012, 2013; Westman et al., 2012;
Yang et al., 2012; Gaser et al., 2013; Liu et al., 2013; Monge-Argilés
et al., 2013; Toledo et al., 2013). Table 5 summarizes the main
characteristics of these studies and their results. Sensitivity and
specificity values of each individual primary study are presented in
Tables 6–8. Sensitivity and specificity values were in line with those
reported in systematic reviews with meta-analyses. Results show
that lot of effort has been put in the combination of different
biomarkers, managing to achieve the highest sensitivity and speci-
ficity values. Most of the recent studies do not only combine the
Table 5 | Summary of primary studies published after the new revised
diagnostic criteria: mean sensitivity and specificity values.
Number of
comparisons
included
Sensitivity Specificity LR+ LR−
Mean
(SD)
Min–
max
Mean
(SD)
Min–
max
AD VS. HEALTHY CONTROLS
Aβ42 11 83 (9) 63–97 80 (8) 67–92 4 0.2
T-tau 12 78 (9) 61–91 82 (14) 53–97 4 0.3
p-tau 12 78 (10) 61–89 77 (18) 37–92 3 0.3
Combination 25 87 (6) 70–98 84 (9) 53–97 5 0.2
AD VS. OTHER DEMENTIAS
Aβ42 5 85 (5) 82–95 61 (24) 22–80 2 0.2
T-tau 4 75 (14) 61–92 71 (22) 40–93 3 0.4
p-tau 4 80 (6) 77–88 78 (15) 56–88 4 0.3
Combination 19 86 (10) 67–100 78 (14) 36–97 4 0.2
MCI-C VS. MCI-S
Aβ42 9 79 (14) 55–91 63 (20) 36–96 2 0.3
T-tau 9 76 (12) 60–88 58 (17) 39–88 2 0.4
p-tau 7 78 (9) 64–85 56 (18) 30–90 2 0.4
Combination 19 84 (10) 57–98 63 (19) 36–95 2 0.3
AD, Alzheimer’s disease; MCI, mild cognitive impairment (MCI-C: MCI-
converters, MCI-S: MCI-stables); SD, standard deviation; LR+, positive likeli-
hood ratio; LR−, negative likelihood ratio; sensitivity and specificity values are
expressed in percentages.
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Table 6 | Primary studies published after the new revised diagnostic criteria (AD vs. Healthy Controls): sensitivity and specificity values.
CSF biomarker and Study AD diagnostic
criteria
Number of
AD patients
Number of
healthy controls
Sensitivity Specificity Specifications
Aβ42
Baldeiras et al. (2012) NINCDS-ADRDA 170 35a 79 73
Bombois et al. (2013) NINCDS-ADRDA 91 37b 77 79
Guo et al. (2013) NINCDS-ADRDA 69 92 78 74
Le Bastard et al. (2013) Neuropathological 51 95 94 88 ELISA
88 92 LUMINEX
Mattsson et al. (2012) NINCDS-ADRDA 529 304 85 82 Age ≤64
85 82 Age 65–74
85 73 Age ≥75
Molinuevo et al. (2013) NINCDS-ADRDA 238 103 87 67
Mouton-Liger et al. (2012) NINCDS-ADRDA 45 35c 97 89
Parnetti et al. (2012) NINCDS-ADRDA 28 28 63 79
T-TAU
Baldeiras et al. (2012) NINCDS-ADRDA 170 35a 78 82
Bombois et al. (2013) NINCDS-ADRDA 91 37b 76 95
Ewers et al. (2012) NINCDS-ADRDA 81 101 64 78
Guo et al. (2013) NINCDS-ADRDA 69 92 61 85
Le Bastard et al. (2013) Neuropathological 51 95 69 94 ELISA
82 87 LUMINEX
Mattsson et al. (2012) NINCDS-ADRDA 529 304 85 74 Age ≤64
85 53 Age 65–74
85 61 Age ≥75
Molinuevo et al. (2013) NINCDS-ADRDA 238 103 82 83
Mouton-Liger et al. (2012) NINCDS-ADRDA 45 35c 91 97
Parnetti et al. (2012) NINCDS-ADRDA 28 28 82 93
p-TAU
Baldeiras et al. (2012) NINCDS-ADRDA 170 35a 82 91
Bombois et al. (2013) NINCDS-ADRDA 91 37b 87 92
Ewers et al. (2012) NINCDS-ADRDA 81 101 67 79
Guo et al. (2013) NINCDS-ADRDA 69 92 61 86
Le Bastard et al. (2013) Neuropathological 51 95 77 78 ELISA
69 91 LUMINEX
Mattsson et al. (2012) NINCDS-ADRDA 529 304 85 67 Age ≤64
85 46 Age 65–74
85 37 Age ≥75
Molinuevo et al. (2013) NINCDS-ADRDA 238 103 82 72
Mouton-Liger et al. (2012) NINCDS-ADRDA 45 35c 89 90
Parnetti et al. (2012) NINCDS-ADRDA 28 28 64 89
COMBINATION OF CSF CORE BIOMARKERS
Baldeiras et al. (2012) NINCDS-ADRDA 170 35a 80 94 T-tau/Aβ42
88 91 Aβ42/p-tau
Bjerke et al. (2011) NINCDS-ADRDA 30 30 93 83 OPLSd
Bombois et al. (2013) NINCDS-ADRDA 91 37b 88 89 T-tau/Aβ42
89 92 Aβ42/T-tau
84 97 Hulstaert’s indexe
Guo et al. (2013) NINCDS-ADRDA 69 92 78 79 LRf
Lampert et al. (2013) NINCDS-ADRDA 62 74 92 66 T-tau/Aβ42 (all)
37 36 95 53 T-tau/Aβ42 (FH+g)
25 38 88 79 T-tau/Aβ42 (FH−h)
(Continued)
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Table 6 | Continued
CSF biomarker and Study AD diagnostic
criteria
Number of
AD patients
Number of
healthy controls
Sensitivity Specificity Specifications
Le Bastard et al. (2013) Neuropathological 51 95 98 91 LRi (ELISA)
94 87 LRi (LUMINEX)
Mattsson et al. (2012) NINCDS-ADRDA 529 304 85 95 Age ≤64 (LRj)
85 83 Age 65–74 (LRj)
85 80 Age ≥75 (LRj)
Molinuevo et al. (2013) NINCDS-ADRDA 238 103 84 88 T-tau/Aβ42
84 87 p-tau/Aβ42
94 86 AD-CSF-index for T-tauk
94 84 AD-CSF-index for p-taul
93 81 Hulstaert’s indexm
Parnetti et al. (2012) NINCDS-ADRDA 28 28 78 89 Aβ42/T-tau
83 82 Aβ42/p-tau
Toledo et al. (2013) NINCDS-ADRDA 92 110 70 82 T-tau/Aβ42
Westman et al. (2012) NINCDS-ADRDA 96 111 84 79 OPLSn
Yang et al. (2012) NINCDS-ADRDA 87 75 SVMo
AD, Alzheimer’s disease.
aNeurological controls, most of them suffering from acute or chronic headaches with no subjective cognitive complaints.
bControls consisted of individuals with psychiatric disorders or other neurological conditions such as headaches, dysarthria, chronic alcoholism, Parkinson’s disease,
multiple sclerosis or drug addiction.
cNeurological controls.
dOPLS: Orthogonal projection to latent structures. The biomarkers contributing the most to the discrimination between AD and controls were in the following order:
Aβ42, T-tau, NF-L (neurofilament light), MMP-10 (myelin basic protein), p-tau-181, H-FABP (heart fatty acid binding protein), and MBP (matrix metalloproteinases).
eHulstaert’s index: Aβ42/[p-tau(3.694+0.0105 T-tau)] (see Hulstaert et al., 1999).
fLR: Logistic regression model including Aβ42, T-tau, and p-tau-181.
gFH+: Family history positive. First-degree relative who has developed late-onset AD.
hFH-: Family history negative.
iLR: Logistic regression model including Aβ42 and T-tau.
jLR: Logistic regression model including Aβ42/p-tau, and T-tau.
kAD-CSF-index forT-tau: [(Aβmax – Aβ42)/(Aβmax – Aβmin)+ (T-tau –T-taumin)/(T-taumax –T-taumin)], where Aβmax andT-taumax represent the 95th percentile of the respective values,
and Aβmin and T-taumin represent the 5th percentile of the distribution values).
lAD-CSF-index for p-tau: [(Aβmax – Aβ42)/(Aβmax - Aβmin)+ (p-tau – p-taumin)/(p-taumax – p-taumin)].
mHulstaert’s index: Aβ42/(240+1.18tau).
nOPLS: The model included Aβ42, T-tau and p-tau.
oSVM: Linear support vector machine, including Aβ42, T-tau and p-tau.
CSF core biomarkers between them by calculating their ratios but
also apply logistic regression models and advanced multivariate
statistical methods. These models allow combining the CSF core
biomarkers with other disease markers (Bjerke et al., 2011; West-
man et al., 2012; Yang et al., 2012). Furthermore, several recent
studies have analyzed the utility of indexes as the AD-CSF-index
(Molinuevo et al., 2013) and the disease state index (DSI) (Muñoz-
Ruiz et al., 2013), and some procedures as the Predict AD tool
(Liu et al., 2013). DSI and PredictAD tool combine the CSF core
biomarkers with demographic data, APOE, cognitive tests, and
neuroimaging data.
It must be noticed that only three studies applied the new
revised diagnostic criteria for AD or classified the MCI patients
according to biomarker evidence of AD pathophysiology (Toledo
et al., 2012; Liu et al., 2013; Monge-Argilés et al., 2013). In addi-
tion, although not reporting sensitivity and specificity values, we
detected six further studies that also applied the new revised
diagnostic criteria (Heister et al., 2011; Galluzzi et al., 2013; Knop-
man et al., 2013; Prestia et al., 2013; Roe et al., 2013). Galluzzi et al.
(2013), Heister et al. (2011), Monge-Argilés et al. (2013) and Pres-
tia et al. (2013) found that progression to AD was more frequent in
MCI patients with increased biological severity based on biomark-
ers. Galluzzi et al. (2013), reported that 100% of MCI patients with
the AD biomarker pattern developed AD, but 0% of the patients
with normal biomarker pattern did so. Heister et al. (2011) and
Monge-Argilés et al. (2013) mostly replicated these results. More-
over, Prestia et al. (2013) showed that conversion from MCI to AD
is not only more frequent among individuals with biomarker pos-
itivity but also occurs earlier. Interestingly, two very recent studies
have reported that individuals in the preclinical AD phase (cogni-
tively normal but with biomarker positivity) have an increased rate
of conversion to MCI (21%) compared to controls with a normal
biomarker profile (7%) (Knopman et al., 2013), and also have a
more rapid progression (Roe et al., 2013).
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Table 7 | Primary studies published after the new revised diagnostic criteria (AD vs. other dementias): sensitivity and specificity values.
CSF biomarker and
Study
AD diagnostic
criteria
Number of
AD patients
Number of non-AD
demented patients
Sensitivity Specificity Specifications
Aβ42
Bibl et al. (2012) NINCDS-ADRDA 22 17 (FTLD) 95 53
de Rino et al. (2012) NINCDS-ADRDA 72 42 (FTLD) 82 22
Gabelle et al. (2013) NINCDS-ADRDA 272 405 (AA, FTLD, LBD, ODD, OND, PSY) 82 71
Le Bastard et al. (2013) Neuropathological 51 15 (CJD, DLB, FTLD, VaD, PDD, SCA) 84 79 ELISA
84 80 LUMINEX
T-TAU
de Rino et al. (2012) NINCDS-ADRDA 72 42 (FTLD) 61 73
Gabelle et al. (2013) NINCDS-ADRDA 272 405 (AA, FTLD, LBD, ODD, OND, PSY) 81 78
Le Bastard et al. (2013) Neuropathological 51 15 (CJD, DLB, FTLD, VaD, PDD, SCA) 65 93 ELISA
92 40 LUMINEX
p-TAU
de Rino et al. (2012) NINCDS-ADRDA 72 42 (FTLD) 88 56
Gabelle et al. (2013) NINCDS-ADRDA 272 405 (AA, FTLD, LBD, ODD, OND, PSY) 77 88
Le Bastard et al. (2013) Neuropathological 51 15 (CJD, DLB, FTLD, VaD, PDD, SCA) 77 80 ELISA
77 87 LUMINEX
COMBINATION
Bibl et al. (2012) NINCDS-ADRDA 22 17 (FTLD) 91 65 Aβ42/Aβ40
82 82 Aβ42/Aβ38
Bjerke et al. (2011) NINCDS-ADRDA 30 26 (MD or sVaD) 89 90 OPLSb
de Rino et al. (2012) NINCDS-ADRDA 72 42 (FTLD) 84 61 T-tau/Aβ42
80 68 p-tau/Aβ42
Gabelle et al. (2013) NINCDS-ADRDA 272 405 (AA, FTLD, LBD, ODD, OND, PSY) 87 79 Aβ42/T-tau
85 84 Aβ42/p-tau
85 87 LRc
Irwin et al. (2012) Neuropathological 11 10 (FTLD) 100 91 T-tau/Aβ42 (ELISA)
Clinical diagnosisa 30 10 (FTLD) 90 97 T-tau/Aβ42 (LUMINEX)
11 10 (FTLD) 100 36 T-tau/Aβ42 (ELISA)
30 6 (FTLD) 67 87 T-tau/Aβ42 (LUMINEX)
Le Bastard et al. (2013) Neuropathological 51 15 (CJD, DLB, FTLD, VaD, PDD, SCA) 88 80 LRd (ELISA)
90 73 LRd (LUMINEX)
Muñoz-Ruiz et al. (2013) DSM-IV 35 37 (FTLD) 70 71 DSIe
Toledo et al. (2012) Neuropathological 71 29 (FTLD) 90 82 LRf (ELISA)
100 88 LRg (LUMINEX)
NIA-AA 71 29 (FTLD) 69 80 LRh (ELISA)
79 78 LRh (LUMINEX)
AD, Alzheimer’s disease; FTLD, frontotemporal lobe degeneration; AA, amyloid angiopathies; DLB, dementia with Lewy bodies; ODD, other neurodegenerative
diseases; ND, other non-neurodegenerative diseases; PSY, psychiatric disorders; CJD, Creutzfeldt–Jakob disease; VaD, vascular dementia; PDD, Parkinson’s disease
dementia; SCA, spinocerebellar ataxia; MD, mixed dementia; sVaD, subcortical vascular dementia.
aClinical diagnosis: criteria applied is not specified.
bOPLS: Orthogonal projection to latent structures. The biomarkers contributing the most to the discrimination between AD and sVaD were in the following order:
MBP (matrix metalloproteinases), TIMP-1 (tissue inhibitor of metalloproteinases), p-tau-181, NF-L (neurofilament light), T-tau, MMP-9 (myelin basic protein), Aβ42, and
MMP-2 (myelin basic protein).
cLR: logistic regression model including p-tau and Aβ42.
dLR: logistic regression model including Aβ42 and p-tau.
eDSI: disease state index, including APOE, Aβ42, T-tau, p-tau, MRI (hippocampal volume, tensor-based morphometry, and voxel-based morphometry), and MMSE.
fLR: logistic regression model including Aβ42 and T-tau.
gLR: logistic regression model including Aβ42 and p-tau.
hLR: logistic regression model including T-tau and p-tau.
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Table 8 | Primary studies published after the new revised diagnostic criteria (MCI-C vs. MCI-S): sensitivity and specificity values.
CSF biomarker and Study AD diagnostic
criteria
Number of
MCI-C patients
Number of
MCI-S patients
Sensitivity Specificity Specifications
Aβ42
Buchhave et al. (2012) NINCDS-ADRDA 72 62a 90 76
Gaser et al. (2013) NINCDS-ADRDA 32 33 91 36 MCI (early progression)d
66 33 89 36 MCI (all)e
Mattsson et al. (2012) NINCDS-ADRDA 271 102b 85 77 Age ≤64
85 56 Age 65–74
85 60 Age ≥75
Parnetti et al. (2012) NINCDS-ADRDA 32 58 56 96
Vos et al. (2013) NINCDS-ADRDA 130 216 75 58 Amnestic MCI
61 131 55 71 Non-amnestic MCI
T-TAU
Ewers et al. (2012) NINCDS-ADRDA 58 72 61 59
Gaser et al. (2013) NINCDS-ADRDA 32 33 84 39 MCI (early progression)d
66 33 88 39 MCI (all)e
Mattsson et al. (2012) 271 102b 85 65 Age ≤64
85 49 Age 65–74
85 46 Age ≥75
Parnetti et al. (2012) NINCDS-ADRDA 32 58 62 88
Vos et al. (2013) NINCDS-ADRDA 130 216 74 61 Amnestic MCI
61 131 60 78 Non-amnestic MCI
p-TAU
Ewers et al. (2012) NINCDS-ADRDA 58 72 64 59
Gaser et al. (2013) NINCDS-ADRDA 32 33 78 58 MCI (early progression)d
66 33 68 58 MCI (all)e
Mattsson et al. (2012) 271 102b 85 55 Age ≤64
85 44 Age 65–74
85 30 Age ≥75
Parnetti et al. (2012) NINCDS-ADRDA 32 58 81 90
COMBINATION
Buchhave et al. (2012) NINCDS-ADRDA 72 62a 88 90 Aβ42/p-tau
82 94 (Aβ42/p-tau)+T-tau
Gaser et al. (2013) NINCDS-ADRDA 32 33 97 42 Aβ42/p-tau (MCI early prog.)d
66 33 92 42 Aβ42/p-tau MCI (all)e
Liu et al. (2013) NIA-AAc 158 233 90 36 Aβ42 or T-tau
57 70 Aβ42 and T-tau
73 71 PredictAD toolf
Mattsson et al. (2012) NINCDS-ADRDA 271 102b 85 86 Age ≤64 (LRg)
85 65 Age 65–74 (LRg)
85 61 Age ≥75 (Lg)
Monge-Argilés et al. (2013) NIA-AAc 15 15 73 73 Aβ42, T-tau and p-tau-181
Parnetti et al. (2012) NINCDS-ADRDA 32 58 94 65 Aβ42/T-tau
81 95 Aβ42/p-tau
Toledo et al. (2013) NINCDS-ADRDA 61 61 80 46 T-tau/Aβ42
Vos et al. (2012) NINCDS-ADRDA 48 105 83 65 Aβ42/T-tau
Vos et al. (2013) NINCDS-ADRDA 130 216 98 38 Aβ42/T-tau (amnestic MCI)
61 131 90 54 Aβ42/T-tau (non-amnestic MCI)
(Continued)
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Table 8 | Continued
CSF biomarker and Study AD diagnostic
criteria
Number of
MCI-C patients
Number of
MCI-S patients
Sensitivity Specificity Specifications
Westman et al. (2012) NINCDS-ADRDA 81 81 76 54 OPLSh
Yang et al. (2012) NINCDS-ADRDA 25 86 80 44 SVMsi
AD, Alzheimer’s disease; MCI, mild cognitive impairment; MCI-C, MCI-converters; MCI-S, MCI-stables.
aMCS-S pooled together with MCI patients that developed other types of dementia at follow-up, including vascular dementia (n= 14), dementia with Lewy bodies
(n=3), frontotemporal lobe degeneration (n=1), Semantic Dementia (n=2), and traumatic brain injury dementia (n= 1).
bMCI-S pooled together with MCI patients that developed other types of dementia at follow-up, including vascular dementia (n=28), dementia with Lewy bodies
(n=14), frontotemporal lobe degeneration (n=7), and neurological diseases and dementia (n=10).
cMCI patients were classified according to the likelihood of AD conversion based on biomarker evidence of AD pathophysiological process (NIA-AA diagnostic criteria:
Albert et al., 2011).
dMCI (early progression): MCI patients that converted to AD within the first 12 months of follow-up.
eMCI (all): MCI early progression+MCI late progression (MCI patients that converted to AD after the first 12 months of follow-up).
fPredictAD tool: including demographic data, APOE, MMSE, ADAS-Cog, neuropsychological battery, Aβ42,T-tau, and several features derived from MRI using FreeSurfer,
manifold learning, hippocampal volume, and Tensor-Based Morphometry.
gLR: Logistic regression model including Aβ42/p-tau, and T-tau.
hOPLS: The model included Aβ42, T-tau and p-tau.
iSVM: Linear support vector machine, including Aβ42, T-tau and p-tau.
Finally, some authors are trying to improve the diagnostic per-
formance of the CSF core biomarkers by controlling for different
factors. For instance, difficulties in predicting MCI progression
to AD could be influenced by the intrinsic heterogeneity of MCI.
Recent studies show several aspects that directly affect the pre-
dictive power of the biomarkers, and should thus be taken into
account when designing future studies and interpreting previous
results. Vos et al. (2013) found that AD biomarkers might not
be as sensitive in non-amnestic MCI as in amnestic MCI. Buch-
have et al. (2012) found that baseline CSF Aβ42 levels were equally
reduced in patients with MCI who converted to AD within 0–
5 years (early converters) compared with those who converted
between 5 and 10 years (late converters). However, CSF T-tau
and p-tau levels were significantly higher in early converters.
This might potentially affect aspects like biomarkers combina-
tion or prediction of early/late converters. Buchhave et al. (2012)
showed that biomarkers combination resulted in a reduction in the
negative predictive value because many patients with MCI who
developed AD after 5–10 years had normal T-tau levels at base-
line. Results reported by Gaser et al. (2013) show that CSF core
biomarkers had generally better performance for early convert-
ers (<12 months) than for late converters (>12 months). Other
studies show the influence of factors such as the age in biomark-
ers performance. Mattsson et al. (2012) found that although the
diagnostic accuracies for AD decreased with age, the predictive
values for a combination of biomarkers remained essentially sta-
ble. Finally, other authors have focused in factors as family history
of AD. Lampert et al. (2013) showed that when comparing AD
patients and healthy controls, T-tau/Aβ42 showed better sensitiv-
ity for individuals with family history of AD, but worse specificity
compared to individuals without family history of AD.
5. DISCUSSION
This meta-review includes seven studies identified in the liter-
ature as systematic reviews with meta-analysis on the topic of
CSF core biomarkers for AD: Bloudek et al. (2011); Diniz et al.
(2008); Mitchell (2009); Monge-Argilés et al. (2010); Schmand
et al. (2010); Sunderland et al. (2003), and Van Harten et al. (2011).
Moreover, it must be emphasized that, according to our systematic
review, no systematic reviews with meta-analysis have been pub-
lished after reviewed criteria for AD were published (May 2011).
Therefore, we also carried out a specific search of primary studies
published from May 2011 to the date of our search (September
2013). Twenty-six primary studies served as the focus for this syn-
thesis. In total, the included systematic reviews with meta-analysis
comprise 317 references, of which 130 are unique or non-repeated.
Seventy-two references compare AD vs. healthy controls (Aβ42: 30,
T-tau: 50; p-tau: 26), 78 studies analyze the discrimination between
AD and other dementias (Aβ42: 11, T-tau: 60; p-tau: 41), and 23
articles compare MCI-C vs. MCI-S (Aβ42: 13, T-tau: 20; p-tau:
15). The diagnostic ability of CSF biomarkers to differentiate AD
from healthy controls and other dementias are the two aspects
that have received more attention in the literature. Regarding the
specific biomarkers, a total of 39 non-repeated references focused
on Aβ42, 103 on T-tau and 60 on p-tau. Noteworthy, Aβ42 is the
less frequently studied biomarker, in spite of its core involvement
in AD, whereas T-tau stands out as the most studied.
Regarding the diagnostic ability of the different CSF core bio-
markers, this meta-review confirms that the combination provides
the highest values of sensitivity and specificity. This is likely due to
that they reflect two aspects of AD pathology, i.e., plaques (Aβ42),
and neurodegeneration (tau). This combination seems to be use-
ful for distinguishing between AD patients and healthy controls, as
well as predicting which MCI patients will progress to dementia. If
the situation would require the use of a single biomarker, T-tau has
the highest values of sensitivity and specificity when comparing
AD and healthy controls. However, no single biomarker at present
is appropriate to differentiate MCI-C from MCI-S. Nevertheless,
the only systematic review with meta-analysis in the literature con-
cerning prediction of MCI was limited to three original studies
Frontiers in Aging Neuroscience www.frontiersin.org March 2014 | Volume 6 | Article 47 | 14
Ferreira et al. CSF biomarkers in Alzheimer’s disease
(Monge-Argilés et al., 2010). Revision of primary studies pub-
lished between 2011 and 2013 helps to clarify this issue. Sensitivity
values are lower than reported by Monge-Argilés et al. (2010) and
the specificity is clearly suboptimal. However, considering factors
such as age, family history of AD and several aspects inherent to
MCI heterogeneity could help to improve the predictive perfor-
mance of CSF biomarkers. For instance, CSF core biomarkers are
more effective in young MCI patients (<64 years) (Mattsson et al.,
2012) amnestic MCI cases (Vos et al., 2013) and early converters
(<12 months) (Gaser et al., 2013).
On the other hand, CSF core biomarkers seem to fail in dis-
tinguishing AD from other dementias, both when used as single
biomarkers or in combination. The reason is that both CSF T-tau
and Aβ42 levels are partially overlapped between AD and DLB,
FTLD, and VaD (Buerger et al., 2007; Hampel et al., 2010; Van
Harten et al., 2011). The combination of different CSF biomark-
ers provides the highest sensibility (86%), but is quite unspecific
(67%) (Bloudek et al., 2011). An exception occurs in the case of
CJD, where T-tau shows optimal performance in discriminating
CJD from AD (Van Harten et al., 2011). In this meta-review, p-tau
arose as the CSF biomarker with the best performance for dif-
ferentiating AD from other dementias, although with sensitivity
and specificity values around 75 and 80%, respectively (Mitchell,
2009; Bloudek et al., 2011; Van Harten et al., 2011). The expla-
nation for this outperforming may be that p-tau is not a simple
marker of axonal damage and neuronal degeneration, as T-tau,
but it is more closely related to AD physiopathology and the for-
mation of neurofibrillary tangles (Anoop et al., 2010; Holtzman,
2011). In addition, CSF p-tau concentrations seem to be more
control-like and less AD-like in DLB, FTLD, and VaD (Van Harten
et al., 2011). Interestingly, different p-tau isoforms might have
differential pathophysiological roles in AD (Buerger et al., 2007;
Engelborghs et al., 2007). There is some evidence indicating that
P-tau231 may improve the differentiation between AD and FTLD
(Buerger et al., 2002; Hampel et al., 2004), while p-tau181 may
improve the differentiation between AD and DLB, and AD and
VaD (Buerger et al., 2002; Hampel et al., 2004). P-tau396–404, and
the ratio of p-tau396–404/T-tau has been shown in one study to dif-
ferentiate AD from VaD (Hu et al., 2002). However, this promising
results must been confirmed in future studies.
The analysis of likelihood ratios provides some valuable hints,
supporting and complementing sensitivity and specificity figures
reported in previous literature and discussed above. Briefly, T-
tau is appropriated to rule-in AD patients when compared to
healthy controls, DLB and VaD, and is conclusive when compared
to CJD. Moreover, p-tau shows good capacity to rule-in AD cases
vs. FTLD, and to rule-out non-AD patients when compared to
VaD. Combination of CSF biomarkers is the best option to rule-
out non-AD cases when compared to healthy controls and mixed
groups of non-AD dementia. It is also the best option to rule-out
non-MCI-C cases, as well as, to rule-in MCI-C patients.
Although the combination of CSF biomarkers provides the
best diagnostic performance, only two systematic reviews with
meta-analysis analyzed such issue (Monge-Argilés et al., 2010;
Bloudek et al., 2011). Furthermore, together the two meta-analyses
included only 14 original studies. In this meta-review we also ana-
lyze 26 further studies published after the new revised diagnostic
criteria. Several findings deserve special attention. P-tau/Aβ42 ratio
possesses higher sensitivity and specificity for differentiating AD
from healthy controls and from other dementias, as compared to
T-tau/Aβ42 ratio (Maddalena et al., 2003; Holtzman, 2011). For
instance, p-tau/Aβ42 ratio seems promising in group separation
between AD and VaD (Jong et al., 2006). The combination of p-
tau/Aβ42 could also efficiently predict progression from MCI to
AD with high efficiency (Hansson et al., 2006; Mattsson et al.,
2009; Buchhave et al., 2012; Parnetti et al., 2012; Roe et al., 2013).
Interestingly, increased tau/Aβ42 ratio in normal individuals has
been associated with an increased risk of conversion from normal
to MCI/very mild dementia in four recent studies (Fagan et al.,
2007; Li et al., 2007; Craig-Schapiro et al., 2010; Roe et al., 2013).
These and other studies support the utility of the CSF biomarkers
to predict appearance of clinical symptoms in cognitively normal
individuals that are at the preclinical phase of AD, or have cognitive
complaints, or harbor some genetic risk (Skoog et al., 2003; Moo-
nis et al., 2005; Fagan et al., 2007; Gustafson et al., 2007; Li et al.,
2007; Stomrud et al., 2007; Ringman et al., 2008; Craig-Schapiro
et al., 2010; Nettiksimmons et al., 2010; Fortea et al., 2011; Rami
et al., 2011; Bateman et al., 2012; Holland et al., 2012; Desikan et al.,
2013; Roe et al., 2013; Van Harten et al., 2013). In addition, the
combination of Aβ42 and Aβ40 might be also useful in AD diag-
nosis and for the differential diagnosis vs. other dementias (Spies
et al., 2010). Although several studies have focused on this ratio
and reported interesting results (Vigo-Pelfrey et al., 1993; Mehta
et al., 2000; Lewczuk et al., 2003; Wiltfang et al., 2003; Schoonen-
boom et al., 2005; Bentahir et al., 2006; Kumar-Singh et al., 2006;
Hansson et al., 2007), this area remains controversial and deserves
more research. Therefore, since these indexes appear to have the
highest diagnostic efficiency, and since different combinations are
possible, future work should pursue in this direction.
In summary, the diagnostic performance of CSF core biomark-
ers for AD is generally satisfactory, with sensitivity and specificity
values above 80%. CSF core biomarkers are optimal for discrim-
inating AD patients from healthy controls. This perhaps is an
artificial contrast not representative of realistic clinical compar-
isons, but may have a useful application in research and clinical
trials (Petersen and Trojanowski, 2009). The combination of CSF
core biomarkers could also be suitable to predict which MCI
patients will progress to dementia. Several recent studies support
the utility of CSF core biomarkers for MCI prognosis (Vos et al.,
2012; Choo et al., 2013; Galluzzi et al., 2013; Prestia et al., 2013).
Single CSF core biomarkers provide unsatisfactory specificity val-
ues (50–81%) (Monge-Argilés et al., 2010). However, prediction
of MCI-C by CSF biomarkers could be optimized using longer
observation periods (>6 years) (Jong et al., 2006; Mattsson et al.,
2009) and controlling several factors as age, MCI subtype and fam-
ily history of AD. Related to this, is the fact that the predictive value
and biomarkers’ utility strongly depend on the stage of the disease
and time to conversion. Buschhave et al. (Buchhave et al., 2012)
showed that Aβ42 performs better than Tau or structural MRI 5–
10 years before conversion to AD, but T-tau and p-tau have better
predictive power 0–5 years before conversion to AD. The high-
est performance of structural MRI is close to AD conversion. In
general, predictive power of advanced MRI techniques in conver-
sion from MCI to AD is greater than of CSF biomarkers (Brys
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et al., 2009; Vemuri et al., 2009; Landau et al., 2010; Walhovd et al.,
2010; Cui et al., 2011; Davatzikos et al., 2011; Schmand et al., 2012;
Westman et al., 2012; Gaser et al., 2013), although some studies
also show comparable predictive power (Jack et al., 2010b; Yang
et al., 2012; Liu et al., 2013; Vos et al., 2013), or even better perfor-
mance of the CSF biomarkers, especially when MRI biomarkers
consisted on clinical measures of hippocampal volume (Bouwman
et al., 2007; Eckerström et al., 2010; Vos et al., 2012). Therefore it
is necessary to move forward in the study of CSF biomarkers and
different combinations. Studies should not only combine the CSF
core biomarkers with each other but also with other biomarkers.
Recent studies show an increase in the diagnostic efficiency of CSF
core biomarkers when combined with neuroimaging biomarkers
(Vos et al., 2012; Westman et al., 2012; Choo et al., 2013; Galluzzi
et al., 2013; Prestia et al., 2013; Shaffer et al., 2013).
Several limitations obstruct the spread of CSF core biomarkers
to the clinical routine (Henry et al., 2013; Sperling and Johnson,
2013; Zetterberg and Blennow, 2013). First, sensitivity and speci-
ficity of the “ideal” biomarker to detect AD should be at least
80% (The Ronald and Nancy Reagan Research Institute of the
Alzheimer’s Association and the national Institute on Aging work-
ing Group, 1998). Higher levels are not easy to be achieved given
that analyses are derived from clinically diagnosed AD cases in
which the diagnostic accuracy already approximates 85% when
validated by the standard pathologic diagnosis at autopsy (Mendez
et al., 1992; Victoroff et al., 1995). A recent study showed that the
use of clinical diagnosis instead of neuropathological diagnosis
led to a 14–17% underestimation of the CSF biomarker accuracy
(Toledo et al., 2012). With the new revised criteria the hope is
to accomplish higher correspondence between clinical diagnosis
and definitive AD postmortem confirmation. It is also necessary
to test the CSF core biomarkers in pathologically confirmed AD
patients. However, only a few studies have addressed this issue
(Shaw et al., 2009; Brunnström et al., 2010; De Jager et al., 2010;
Irwin et al., 2012; Toledo et al., 2012; Le Bastard et al., 2013).
For this reason, we did not include a specific section in the current
meta-review. Indeed, further original studies are mandatory before
we can extract definitive conclusions regarding the diagnostic
performance of CSF core biomarkers when compared to patho-
logically confirmed AD cases. Finally, since AD is a multifactorial
neurodegenerative disorder both at clinical and neuropathological
level, development of biomarkers with 100% efficiency in terms of
sensitivity and specificity is difficult to achieve.
A second limitation is the variability between studies in the
characteristics of the groups included and the diagnostic criteria
used. This is true at different levels. Regarding healthy controls, in
some occasions individuals with subjective memory complaints
and neurological or psychiatric patients have been included as
controls (Nägga et al., 2002; Buerger et al., 2003; Schoonenboom
et al., 2004; Mitchell, 2009; Mouton-Liger et al., 2012; Bombois
et al., 2013). Other studies have mixed healthy controls together
with MCI-S patients (Diniz et al., 2008). It is even more alarming
that quite many studies actually do not clearly specify what kind
of participants are included as healthy controls. As lumbar punc-
ture is not easily achieved in healthy volunteers, an amalgamate
of non-demented patients is usually included instead. Regarding
MCI, AD and other dementias, a relevant aspect is the lack of
standardization in the clinical criteria used for diagnoses, espe-
cially for VaD. MCI is a heterogeneous condition (Petersen, 2004),
having a large percentage of them an underlying diagnosis that
is not AD (Fagan et al., 2007; Shaw et al., 2009). In AD stud-
ies, AD-like MCI is necessary to be guaranteed. Recently revised
diagnostic criteria for MCI (Albert et al., 2011) can add great ben-
efit to this regard. Other aspect that critically affects sensitivity
and specificity values is the great heterogeneity in follow-up peri-
ods among MCI studies (Diniz et al., 2008). Studies with longer
follow-up periods normally provide higher diagnostic efficiency
(Jong et al., 2006; Mattsson et al., 2009). In relation to AD, most
studies so far have used the NINCDS-ADRDA criteria, although a
small percentage of studies have applied different criteria instead
(Schmand et al., 2010). New proposed criteria must still be tested
(McKhann et al., 2011). A critical issue is the possible circularity for
the study of CSF biomarkers, given that now they are part of the
diagnostic criteria. Regarding studies analyzing the comparison
between AD and other dementias, an aspect that also affects the
results and conclusions is that different forms of non-AD demen-
tias are usually pooled together (Mitchell, 2009; Bloudek et al.,
2011). Therefore, we highly recommend and encourage that future
studies clearly specify groups’ characteristics, especially in regard
to the control group, as well as the diagnostic criteria used for
pathological groups. Also studies should specify whether sporadic
or familial AD cases are included or in what proportion, in case
they are combined. Likewise, age and sex should be accounted for
as confounding factors.
A third limitation is the variability in methodological aspects
of the technique in itself. Different organizations as the Interna-
tional Alzheimer’s Association (AA), the Alzheimer’s Biomarkers
Standardization Initiative (ABSI), or The Penn Biomarker Core
on Alzheimer’s Disease Neuroimaging Initiative (ADNI), are car-
rying out intense efforts to standardize the technical procedures.
The AA has recently begun a program of quality control (QC)
on CSF biomarkers for AD. Preliminary conclusions indicate that
the standardization of laboratory procedures could contribute to
reduce variability in the results and increase the utility of these bio-
markers (Hansson et al., 2006; Fagan et al., 2011; Mattsson et al.,
2011). Likewise, the ABSI has done an important contribution
reviewing potential pre-analytical factors influencing the quan-
titative outcomes of AD biomarker assays and providing several
recommendations [see Vanderstichele et al. (2012)].
In relation to the absence of a technical standardization is
the variability in cut-off values to interpret CSF core biomarker
levels. Differences between studies may reflect differences in labo-
ratory methods, suggesting an inter-laboratory variation of results
(Lewczuk et al., 2006). Recently, new methodologies have been
introduced achieving less intra- and inter-assay variability as com-
pared to standard methods such as ELISA (Innogenetics, Ghent,
Belgium) (e.g., xMAP–Luminex) (Olsson et al., 2005). Standard-
ized procedures are mandatory in order to obtain valid results.
Due to inter-laboratory variability, at present, optimal cut-off
values should be based on individual laboratory reference val-
ues rather than on values obtained from the literature. For this
reason, proposing universal cut-offs values in this meta-review
is difficult. Nevertheless, two options might temporarily solve
this situation meanwhile strict standardizations are done. First,
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some authors suggest performing a systematic numeric normal-
ization to account for this variability (Hansson et al., 2006). The
exact variability this method introduces is unclear and deserves
further specific review. Second, another potential solution is the
novel proposal of a normalized index (the AD-CSF-index), which
was recently validated to discriminate AD vs. controls in different
European populations (Molinuevo et al., 2012, 2013). This index
improves the diagnosis of AD by combining the normalized values
of Aβ42 with T-tau or p-tau. It has shown higher sensitivity and
specificity than the combination of direct values of the different
CSF core biomarkers and avoids potential false positives associated
with Aβ42 presence in the preclinical stage.
Finally, a fifth limitation concerns recruitment procedures.
In high prevalence settings such as memory clinics where the
prevalence of dementia is 30–50% (Feldman et al., 2003), reason-
ably high sensitivity and specificity values are expected. However,
lower diagnostic performance is obtained in primary care, where
the prevalence of dementia is approximately 15% (Ólafsdóttir
et al., 2000). It is therefore necessary to specify patients source,
as part of groups’ characteristics as we stated above. However, this
information is not always provided in the studies. For instance,
among the systematic reviews with meta-analysis included in
this meta-review, only Mitchel (Mitchell, 2009) specified such
information.
Cerebrospinal fluid core biomarkers remain quite promising.
However, limitations discussed above must be urgently overcome.
These CSF biomarkers tend to gain accuracy when assessed earlier
in the disease process. We believe that this inherent characteristic
should be promoted using them for the early diagnosis in pre-
clinical stages of the disease and prediction from asymptomatic or
MCI to AD. Studies with longer follow-up intervals in middle-age
or elderly subjects who are normal at baseline are needed to test
this potential. Regarding these kind of studies, research in normal
subjects with increased risk for the development of AD is of great
interest (Risacher and Saykin, 2013).
6. CONCLUSION AND PERSPECTIVE
This meta-review describes the state-of-the-art on CSF core bio-
markers for AD in the context of new revised diagnostic criteria.
Likewise, we offer a critical, integrated and systematic overview
of the so far disperse information about the diagnostic efficiency
and utility of CSF Aβ42, T-tau and p-tau, to distinguish AD from
healthy controls, AD from other dementias, and to predict pro-
gression from MCI to AD. We have also thoroughly discussed main
limitations in the field at the time being. A more detailed treatment
of relevant issues such as performance of CSF core biomarkers in
pathologically confirmed AD cases, heterogeneity of healthy and
pathological groups, carelessness of confounding factors such as
age and sex, and proposal of universal cut-offs values, are however
far away from the aims of this meta-review. These are still open
questions in the current literature and deserve much more specific
revision.
Cerebrospinal fluid Aβ42, T-tau, and p-tau fulfill the criteria
for diagnostically useful biomarkers in AD, and have been suffi-
ciently validated in a large number of mono- and multi-center
studies. They show potential usefulness for clinical practice due
to their established ability to reduce misclassification rates when
compared with the sole application of clinical/neuropsychological
assessment (Mitchell et al., 2010). Moreover, in clinical trials, CSF
core biomarkers can be useful to enrich the samples with pure
AD cases, for patient stratification, as safety markers, and to detect
and monitor the biochemical effects of drugs (Aluise et al., 2008;
Hampel et al., 2008; Petersen and Trojanowski, 2009; Blennow
et al., 2010).
However, despite promising results, CSF core biomarkers are
not currently suitable for its wide implementation in the clinical
routine as core elements for diagnostic criteria (Sperling and John-
son, 2013). Clinical diagnosis is still paramount and biomarkers
are complimentary (Jack et al., 2011). This meta-review shows that
CSF core biomarkers are optimal for discriminating AD patients
from healthy controls. The combination of CSF biomarkers could
be also suitable to predict which MCI patients will progress to
dementia. However, CSF biomarkers fail at present to distinguish
AD from other dementias. Recently revised criteria for AD include
CSF core biomarkers together with neuroimaging biomarkers in
the diagnostic algorithm (McKhann et al., 2011). Much additional
work needs to be done to validate the application of biomark-
ers as they are proposed in new revised criteria. Nonetheless, CSF
core biomarkers for AD show high potential value and leave room
for improvement. In addition, other new candidate CSF biomark-
ers could potentially serve important functions in diagnostics and
drug development if successfully validated in future studies (Rosén
and Zetterberg, 2013). Upcoming investigations should also insist
on plasma biomarkers, given that its use in the clinical routine
is presumably easier. A more general use of CSF biomarkers in
clinical practice will be of great importance. Suitable CSF bio-
markers may help to diagnose AD at an early stage, which is of
great importance when effective treatments for AD can be admin-
istered. Moreover, they may be used to monitor disease progression
and target the right populations or used as an outcome measure
for clinical trials.
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APPENDIX
Table A1 | Search strategy for MEDLINE (OVID) database.
1 *Alzheimer disease/cf, di (cerebrospinal fluid, diagnosis)
2 *Cognition disorders/cf, di, ge, ps (cerebrospinal fluid,
diagnosis, genetics, pathology)
3 1 or 2
4 *Amyloid-beta-peptides/cf, du (cerebrospinal fluid,
diagnostic use)
5 *Biological Markers/an, cf (analysis, cerebrospinal fluid)
6 *tau Proteins/cf (cerebrospinal fluid)
7 Phosphorylated tau.mp
8 Total-tau.mp
9 T-tau.mp
10 p-tau.mp
11 A beta-42.mp
12 *Cerebrospinal Fluid/an, di (analysis, diagnosis)
13 Cerebrospinal Fluid.mp.
14 CSF bioMarker.mp.
15 csf.mp.
16 Or/4-15
17 3 and 16
18 Limit 17 to “diagnosis (best balance of sensitivity and
specificity)”
19 Limit 18 to humans
Table A2 | Search strategy for EMBASE (Elsevier) database.
1 ’alzheimer disease’/mj
2 ’cognitive defect’/mj
3 1 OR 2
4 ’amyloid-beta protein’/mj
5 ’biological marker’/mj
6 ’tau protein’/mj
7 ’phosphorylated tau’:ab,ti
8 ’total-tau’:ab,ti
9 ’t-tau’:ab,ti
10 ’p-tau’:ab,ti
11 ’a beta-42’:ab,ti
12 ’cerebrospinal fluid’/mj
13 ’cerebrospinal fluid’:ab,ti
14 ’csf biomarker’:ab,ti
15 csf:ab,ti
16 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13
OR 14 OR 15
17 3 AND 16
18 ’sensitivity and specificity’/exp
19 sensitivity:ab,ti
20 specificity:ab,ti
21 ((’pre test’ OR pretest) NEAR/8 probability):ab,ti
22 ’post-test probability’:ab,ti
23 ’predictive value?’:ab,ti
24 ’likelihood ratio?’:ab,ti
25 ’diagnostic accuracy’/mj
26 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25
27 17 AND 29
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Table A3 | Strategies followed to reduce the risk of bias.
PUBLICATION BIAS AND REVIEWER SELECTION BIAS
1 Strict inclusion criteria for reviews
Only systematic reviews where included, which attempts to collate all empirical evidence that fits pre-specified eligibility criteria. Systematic
reviews use explicit and systematic methods that are selected to minimize bias
2 Manual query of relevant studies in systematic reviews
Possible publication and reviewer selection bias in included systematic reviews was assessed and minimized by supplementing literature review
with manual query of relevant studies within systematic reviews’ citations
3 Systematic review of primary studies
Evidence was rigorously reviewed in order to minimize both publication and reviewer selection bias
4 Examination of missing results or data
Both systematic reviews and primary studies were carefully examined for clues suggesting that there may be missing results or data.
DATA AVAILABILITY BIAS
5 Assessments were completed independently by more than one reviewer
Two reviewers (DF, LP) independently sought for detailed data in all identified studies. Peer review was done independently and in case of doubt
and/or disagreements a third reviewer (PS) was consulted
METHODOLOGICAL QUALITY
6 Oxman’s scale
Methodological quality of included systematic reviews with meta-analyses was critically appraised with the Oxman’s scale. Assessment was
performed in a blind manner by two reviewers (DF y LP), independently, and in case of doubt and/or disagreements, a third reviewer (PS) was
consulted
7 PRISMA statement for reporting systematic reviews with meta-analyses
Reporting transparence of the different systematic reviews was assessed with PRISMA checklist. Assessment was performed in a blind manner
by two reviewers (DF y LP), independently, and in case of doubt and/or disagreements, a third reviewer (PS) was consulted
DF: Daniel Ferreira; LP: Lilisbeth Perestelo-Pérez; PS: Pedro Serrano-Aguilar.
Table A4 | Methodological quality of selected systematic reviews with meta-analyses according to Oxman’s Scale.
Study Total
score (/10)
Clinical
question (/2)
Criteria
selection (/2)
Relevant studies
covered (/2)
Validity (/2) Combination of
results (/2)
Bloudek et al. (2011) 8 2 2 2 0 2
Diniz et al. (2008) 8 2 2 2 1 1
Mitchell (2009) 8 2 1 2 2 1
Monge-Argilés et al. (2010) 7 2 2 1 1 1
Schmand et al. (2010) 7 2 2 1 0 2
Sunderland et al. (2003) 8 2 2 2 1 1
Van Harten et al. (2011) 7 2 2 2 0 1
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Table A5 | PRISMA checklist of items for reporting systematic reviews with meta-analyses.
Study T
it
le
A
b
st
ra
ct
In
tr
o
d
u
ct
io
n
M
et
h
o
d
s
R
es
u
lt
s
D
is
cu
ss
io
n
Fu
n
d
in
g
Items 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Bloudek et al. (2011) X X Xa X X X X X X X X X X X X
Diniz et al. (2008) X X Xa X X X X X X X X X X X X X X X
Mitchell (2009) X X Xa X X X X X X X X X X X X X X X X X X
Monge-Argilés et al.
(2010)
X X X X X X X X X X X X X X X X
Schmand et al. (2010) X X X X X X X X X X X X X X X X X X X X X X X X X
Sunderland et al. (2003) X Xa X X X X X X X X X X X X X X X
Van Harten et al. (2011) X X X X X X X X X X X X X X X X
X – PRISMA item fulfilled;
aobjectives are explicitly stated but PICOS are not specified (PICOS, participants, interventions, comparisons, outcomes, and study design); PRISMA Items: (1) Title;
(2) Structured summary; (3) Rationale; (4) Objectives; (5) Protocol and registration; (6) Eligibility criteria; (7) Information sources; (8) Search; (9) Study selection; (10)
Data collection process; (11) Data items; (12) Risk of bias in individual studies; (13) Summary measures; (14) Synthesis of results; (15) Risk of bias across studies; (16)
Additional analyses; (17) Study selection; (18) Study characteristics; (19) Risk of bias within studies; (20) Results of individual studies; (21) Synthesis of results; (22)
Risk of bias across studies; (23) Additional analysis; (24) Summary of evidence; (25) Limitations; (26) Conclusions; (27) Funding.
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